Posted by Nalod:
Briggy,
You got a target for Immu??
I have free shares--so I will let them ride and see where it goes. If I have them for 3 months or 3 years it doesnt matter to me. I took the base capital out of two small caps and redeployed some of it.
Posted by Nalod:
You still loving HYGS?
That was a pretty long time ago--like 2 years? That brought back a juicy return in less than 8 months. It's pretty cheap now but the same environment[when gas jacked up] isnt here to propel that thing right now.
Posted by Nalod:
Briggy,
You got a target for Immu??
I have read 8 a couple of times - I was investing in a company DNDN who was similar and they popped up to 18 a few times then back down to 5, recently they hit 23+ and have maintained it. It all depends on how phase 3 goes and whether or not they get FDA approval but with the partnerships lining up I think this is a good hold for a bit.
Today looks like its going to be a good day. Up 84% in after hours trading? Am I reading that right? Thank you Briggs!
Posted by Andrew:
Today looks like its going to be a good day. Up 84% in after hours trading? Am I reading that right? Thank you Briggs!
This one of the Briggs picks I didn't fucking make. Motherfucking piece of shit unlucky bastard that I am. FUCK FUCK FUCK!
Posted by Silverfuel:
Posted by Andrew:
Today looks like its going to be a good day. Up 84% in after hours trading? Am I reading that right? Thank you Briggs!
This one of the Briggs picks I didn't fucking make. Motherfucking piece of shit unlucky bastard that I am. FUCK FUCK FUCK!
Don't worry, its only up 46% so far this morning!
haha I moved my position to some bank preferreds that are currently getting slaughtered so dont feel too bad
Posted by Andrew:
+61.03%
This thing will end up going to the 30s I have a feeling over the next 1-2 years. I kind of wish I powered up on this a lot more and I ended up taking base capital out. 17 a point is still 17 a point--not necessary to be greedy.[yeah right
]
A stock I have taken notice of is BIEL. A lot of good press and results around this penny stock. FDA approval is expected by 9/15 and they are going to be filing 3 more 510k soon.
I invest, so Im gonna ride this for the long run.
Incubate good ideas and be patient. I did very well the last year taking small positions on really down and out things.
No house on nantucket yet!!!!
IGOI looks like it might be ready to pop soon. Technical breakout after 90? Needs the vol to do that.
Briggy,
Whats your take on this?
Brian Orelli
August 28, 2009
All but left for dead at $0.84 per share back in March, Immunomedics (Nasdaq: IMMU) is back with a bang. The stock climbed 60% Thursday after the company reported results from a phase 2 trial testing its epratuzumab drug in patients with lupus.
That mouthwatering six-month return may have gotten Immunomedics (back) on your radar screen, but I'd recommend treading lightly, Fools. Lupus is where drugs go to die, and epratuzumab is a drug that has already died a few times and come back to life.
Sure, epratuzumab could follow in the footsteps of Benlysta, from GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences (Nasdaq: HGSI), and pass its phase 3 trial, but it could also stumble and end up where Biogen Idec (Nasdaq: BIIB), Teva Pharmaceutical (Nasdaq: TEVA), BioMarin Pharmaceuticals (Nasdaq: BMRN), and so many others have thrown their failed drugs.
Then again, epratuzumab seems to be an unkillable zombie, so maybe it would be right at home in the graveyard. In 2004, Amgen (Nasdaq: AMGN) gave Immunomedics back the rights to epratuzumab after a four-year partnership because Amgen didn't think it was worth running a phase 3 trial to test the drug in patients with non-Hodgkin's lymphoma. A few years later, the Food and Drug Administration put a hold on a lupus trial, since lifted, after a new partner, UCB, became worried about the sterility of epratuzumab made by Immunomedics.
If you've got a high risk tolerance, Immunomedics might be a reasonable bet still at this point -- it's down about 12% today. Its market cap is a fifth of Human Genome Sciences', which is also developing a lupus drug, so there's still plenty of upside, if the phase 3 trial is successful.
But that's still a big if.
--------------------------------------------------------------------------------
Posted by Nalod:
Briggy,
Whats your take on this?
Brian Orelli
August 28, 2009
All but left for dead at $0.84 per share back in March, Immunomedics (Nasdaq: IMMU) is back with a bang. The stock climbed 60% Thursday after the company reported results from a phase 2 trial testing its epratuzumab drug in patients with lupus.
That mouthwatering six-month return may have gotten Immunomedics (back) on your radar screen, but I'd recommend treading lightly, Fools. Lupus is where drugs go to die, and epratuzumab is a drug that has already died a few times and come back to life.
Sure, epratuzumab could follow in the footsteps of Benlysta, from GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences (Nasdaq: HGSI), and pass its phase 3 trial, but it could also stumble and end up where Biogen Idec (Nasdaq: BIIB), Teva Pharmaceutical (Nasdaq: TEVA), BioMarin Pharmaceuticals (Nasdaq: BMRN), and so many others have thrown their failed drugs.
Then again, epratuzumab seems to be an unkillable zombie, so maybe it would be right at home in the graveyard. In 2004, Amgen (Nasdaq: AMGN) gave Immunomedics back the rights to epratuzumab after a four-year partnership because Amgen didn't think it was worth running a phase 3 trial to test the drug in patients with non-Hodgkin's lymphoma. A few years later, the Food and Drug Administration put a hold on a lupus trial, since lifted, after a new partner, UCB, became worried about the sterility of epratuzumab made by Immunomedics.
If you've got a high risk tolerance, Immunomedics might be a reasonable bet still at this point -- it's down about 12% today. Its market cap is a fifth of Human Genome Sciences', which is also developing a lupus drug, so there's still plenty of upside, if the phase 3 trial is successful.
But that's still a big if.
--------------------------------------------------------------------------------
Im watching it. I sold all big cap holdings and took a hard short position quad Q. The only stocks I am long pertaining to anything I have said here are GSIT IGOI ARIA and I have free riding shares on IMMU and imph.
[Edited by - BRIGGS on 09-01-2009 12:10 PM]
I sold half my Immu which is my profit remaining this morning when it was up 12%. WTF, it was a good trade.
Thanks!
Posted by Nalod:
I sold half my Immu which is my profit remaining this morning when it was up 12%. WTF, it was a good trade.
Thanks!
Nalod--there are always going to be fish who are able to swim upstream.
Once I saw support levels on the S+P and Nasdaq coming close to being breached I dumped all big caps and Im up nearly 1 1/2 points on the Quad Q short. Right now you want to be 75-90% cash sit back and see where the market can find strong support. I don't suspect anytime soon
[Edited by - BRIGGS on 09-02-2009 4:33 PM][Edited by - BRIGGS on 09-02-2009 6:08 PM]
Briggs, Do you ever play the gold and Silver Mining stocks? What is your take on gold?
Re: ARIA - From what I read, ARIA is supposed to get a review by the FDA on its new drug at the end of Sept. So that could really pop with a favorable outcome. Meanwhile ARIA keeps moving upward. Now at $2.25...I only have a small position so I am thinking to buy some more.
[Edited by - markji on 09-04-2009 09:20 AM]
Posted by Markji:
Briggs, Do you ever play the gold and Silver Mining stocks? What is your take on gold?
Re: ARIA - From what I read, ARIA is supposed to get a review by the FDA on its new drug at the end of Sept. So that could really pop with a favorable outcome. Meanwhile ARIA keeps moving upward. Now at $2.25...I only have a small position so I am thinking to buy some more.
[Edited by - markji on 09-04-2009 09:20 AM]
Gold is way to expensive. I think IGOI is about to really move--resistance was just taken out so it could move to 1.00+ in a hurry. I would really like to see a 1 to 5-7$ type move--it has moved in the past 1 to 13.
Posted by BRIGGS:
Posted by Markji:
Briggs, Do you ever play the gold and Silver Mining stocks? What is your take on gold?
Re: ARIA - From what I read, ARIA is supposed to get a review by the FDA on its new drug at the end of Sept. So that could really pop with a favorable outcome. Meanwhile ARIA keeps moving upward. Now at $2.25...I only have a small position so I am thinking to buy some more.
[Edited by - markji on 09-04-2009 09:20 AM]
Gold is way to expensive. I think IGOI is about to really move--resistance was just taken out so it could move to 1.00+ in a hurry. I would really like to see a 1 to 5-7$ type move--it has moved in the past 1 to 13.
Already in IGOI and it is moving up! :-)
Posted by Markji:
Briggs, Do you ever play the gold and Silver Mining stocks? What is your take on gold?
Re: ARIA - From what I read, ARIA is supposed to get a review by the FDA on its new drug at the end of Sept. So that could really pop with a favorable outcome. Meanwhile ARIA keeps moving upward. Now at $2.25...I only have a small position so I am thinking to buy some more.
[Edited by - markji on 09-04-2009 09:20 AM]
I was under the impression we wouldn't hear about Phase III until December?
Posted by OasisBU:
Posted by Markji:
Briggs, Do you ever play the gold and Silver Mining stocks? What is your take on gold?
Re: ARIA - From what I read, ARIA is supposed to get a review by the FDA on its new drug at the end of Sept. So that could really pop with a favorable outcome. Meanwhile ARIA keeps moving upward. Now at $2.25...I only have a small position so I am thinking to buy some more.
I was under the impression we wouldn't hear about Phase III until December?
Yep - you are correct. What they are doing by Sept 30 is
Ariad Pharmaceuticals (ARIA)
The folks at ARIA are scheduled to release the first interim analysis from a Phase 3 study of their cancer drug ridaforolimus (rida) on or before September 30. Rida is indicated for rare soft tissue and bone sarcomas. The company expects to provide the results from a second interim analysis in Q1 2010 or no later than March 31, 2010. With positive results from the second interim analysis, the company will file an NDA requesting early approval for the drug. If granted priority review from regulators, then rida could be approved as early as Q4 2010.
Like ALTH’s drug PTX, ARIA’s rida is also an orphan drug. Unlike ALTH, however, ARIA has a collaboration agreement with Merck (MRK), which is valued at or near $1 billion.
http://seekingalpha.com/article/159255-f...
